Streetbeat News

DMAC

DiaMedica Therapeutics Inc.

https://www.diamedica.com

Industry

Biotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q4 earnings on March 19, 2024, with an EPS of $-0.14, matching the estimated earnings. The revenue remained unchanged from the same period last year. In the previous quarter, DMAC beat EPS estimates by $0.01, leading to a 7% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:25 pm

DiaMedica Therapeutics reported Q3 EPS of $(0.12), surpassing the consensus estimate of $(0.13) by 7.69%. The EPS figure remains the same as the previous year's same quarter.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:57 pm

Numerous companies are scheduled to report their earnings on November 13, 2023, both before the bell and after. The list includes a wide range of industries and market caps, with some companies expected to report profits while others are anticipated to report losses. Key companies reporting include Tyson Foods, Henry Schein, and AECOM, with expected earnings per share of $0.29, $1.32, and $0.98 respectively. Other companies like IM Cannabis, Roivant Sciences, and Genius Sports are projected to report losses.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 11:40 am

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to release its quarterly earnings report on Monday, 2023-11-13, with analysts predicting an EPS of $-0.13. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, DMAC's stock price has reacted to both earnings outcomes and guidance. Last quarter, DMAC beat the EPS estimate by $0.02, leading to a 4.4% stock price increase the following day. Over the last year, DMAC shares have risen by 101.7%, trading at $2.35 as of November 09.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

DiaMedica Therapeutics reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.18) by 11.11%. However, this is a 23.08% decrease over losses of $(0.13) per share from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

August 14, 2023 | 8:48 pm

Benzinga has released its top ratings upgrades and downgrades for June 22, 2023, including several companies such as DiaMedica Therapeutics, Kellogg, Agree Realty, Grab Holdings, XP Inc, Dow Inc, AES Corp, Celanese Corp, and more. The list also includes initiations of coverage for companies like Iridium Communications, Everest Re Group, Zura Bio, Humacyte, FingerMotion, Outbrain, Taboola.com, Terns Pharmaceuticals, and others.

Portfolio Pulse from Benzinga Insights

June 22, 2023 | 3:02 pm

Oppenheimer analyst Francois Brisebois upgraded DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announced a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

June 22, 2023 | 11:16 am

DiaMedica Therapeutics has raised $37.5 million through a private placement, issuing 11.01 million common shares at $3.40 per share. The proceeds will be used to fund the development of DM199, including the ReMEDy2 clinical trial, and for general corporate purposes. The FDA has also lifted the clinical hold on the ReMEDy2 trial.

Portfolio Pulse from Nabaparna Bhattacharya

June 21, 2023 | 3:40 pm

DiaMedica Therapeutics (NASDAQ:DMAC) has announced a $37.5 million private placement of 11,011,406 common shares at $3.40 per share. The proceeds will be used to fund clinical and product development activities for DM199, including the ReMEDy2 clinical trial. The FDA has also removed the clinical hold on the ReMEDy2 trial.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:42 pm

DiaMedica Therapeutics (NASDAQ:DMAC) announced that the FDA has removed the clinical hold on its ReMEDy2 phase 2/3 trial for DM199 in the treatment of acute ischemic stroke (AIS). The trial is set to resume as soon as possible, with the potential to serve as a pivotal registration study of DM199 in this patient population.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.